Replimune melanoma drug wins support of FDA panel
AdCompositivePositive
AI Analysis
Summary
Replimune's melanoma drug received a positive vote from an FDA advisory panel despite lingering concerns from FDA scientists, positioning the company to advance after two previous rejections.
Outcome Details
FDA advisory panel voted in support despite persistent concerns from FDA scientists
Importance:8/10
Sentiment:
0.70
FDA approval processadvisory committeemelanomaregulatoryresubmission
Read the original article
Published by BioPharma Dive on July 30, 2026 9:25 PM